Skip to main content

Table 3 Between-group analysis and within-group analysis of the primary and secondary outcomes

From: Resistance exercise improves muscle strength, health status and pain intensity in fibromyalgia—a randomized controlled trial

Measures

Resistance exercise (experimental)

Relaxation therapy (control)

Between-group analysis of change

Baseline

Post test

Post-test- baseline

Within-group analysis

Baseline

Post test

Post-test- baseline

Within-group analysis

(n = 67)

(n = 56)

(n = 56)

(n = 63)

(n = 49)

(n = 49)

Mean (SD)

Mean (SD)

Δ (SD)

p value

Mean (SD)

Mean (SD)

Δ (SD)

p value

p value

Median (min; max)

Median (min; max)

Δ (min; max)

 

Median (min; max)

Median (min; max)

Δ (min; max)

Primary outcome

Isometric knee-extension force, N

330.1 (109.4)

356.2 (118.9)

30.4 (71.9)

0.002

298.8 (107.8)

276.4 (112.9)

−8.8 (70.0)

0.644

0.010

326 (111; 643)

342 (105; 663)

31 (−157; 178)

287 (51; 534)

278 (41; 595)

−10 (−222; 132)

Secondary outcomes

FIQ total, 0–100

60.5 (14.4)

54.4 (18.2)

−5.7 (15.0)

0.009

61.1 (17.3)

59.3 (16.0)

0.1 (12.9)

0.71

0.038

59 (31; 95)

55 (11; 88)

−3 (−51; 20)

61 (17; 88)

61 (21; 86)

1 (−34; 25)

Current pain intensity, VAS

49.3 (23.9)

38.6 (25.2)

−11.5 (25.1)

0.002

52.4 (18.3)

53.4 (20.0)

−1.5 (16.5)

0.63

0.033

50 (5; 100)

31 (0; 95)

−13 (−83; 48)

51 (10; 88)

56 (10; 86)

−2 (−51; 30)

6MWT, m

556.6 (75.1)

579.7 (73.7)

18.4 (65.1)

0.002

540.7 (64.5)

533.9 (73.1)

−5.6 (43.5)

0.51

0.003

566 (360; 766)

582 (340; 762)

24 (−290; 196)

530 (362; 660)

537 (366; 656)

1 (−125; 101)

Isometric elbow flexion force, kg

13.0 (5.4)

14.8 (5.6)

2.4 (3.3)

<0.001

10.9 (5.2)

11.7 (5.6)

1.2 (3.3)

0.020

0.020

13 (2; 32)

15 (2; 27)

2 (−5; 12)

10 (2; 24)

12 (3; 27)

1 (−7; 13)

Hand-grip force, N

161.8 (68.7)

181.1 (61.5)

20.1 (36.1)

<0.001

139.4 (61.7)

147.2 (66.7)

14.0 (37.9)

0.013

0.49

164 (34; 319)

185 (38; 327)

14 (−32; 158)

134 (40; 311)

146 (39; 327)

9 (−101; 98)

SF36 PCS, 0–100

31.2 (7.9)

34.5 (9.1)

3.3 (7.2)

0.004

29.9 (8.1)

30.7 (8.3)

0.8 (5.7)

0.28

0.11

31 (12; 50)

35 (14; 54)

3 (−13; 18)

30 (10; 50)

30 (17; 47)

1 (−13; 13)

SF36 MCS, 0–100

37.7 (12.2)

42.0 (12.6)

3.3 (10.3)

0.007

39.6 (12.1)

38.8 (12.9)

−0.4 (9.5)

0.86

0.054

37 (10; 61)

44 (12; 62)

3 (−23; 35)

42 (16; 59)

41 (13; 61)

0 (−22; 23)

PDI, 0–70

35.3 (12.2)

32.2 (13.1)

−3.8 (10.6)

0.006

35.0 (12.5)

35.7 (12.4)

1.4 (9.0)

0.27

0.005

36 (8; 69)

34 (7; 67)

−5 (−29; 23)

34 (7; 61)

38 (9; 58)

0 (−19; 21)

CPAQ, 0–120

63.6 (16.1)

69.6 (15.2)

5.7 (13.1)

0.002

62.4 (17.1)

63.4 (19.1)

0.1 (11.8)

0.79

0.043

63 (19; 106)

69 (34; 98)

6 (−27; 46)

61 (15; 107)

60 (30; 113)

2 (−38; 23)

FABQphysical, 0–24

9.7 (6.1)

8.9 (6.1)

−0.8 (7.0)

0.36

11.2 (6.1)

10.3 (6.3)

−1.3 (5.6)

0.24

0.92

9 (0; 24)

8 (0; 22)

−1 (−19;19)

11 (0; 24)

9 (0; 24)

0 (−18;10)

FABQwork, 0–42

17.2 (12.7)

17.8 (13.1)

0.4 (8.9)

0.83

15.9 (12.1)

16.67 (12.5)

1.2 (8.1)

0.54

0.79

16 (0; 42)

16 (0; 42)

0 (−27; 29)

12 (0; 42)

14 (0; 42)

0 (−19; 30)

  1. Missing values at baseline: Resistance exercise group, SF36 PCS and SF36 MCS, n = 1; FABQwork, n = 6, FABQphysical, n = 1; Relaxation therapy group, CPAQ, n = 1; FABQwork, n = 8. Missing post-test values: Resistance exercise group, SF36 MCS and PCS, n = 3; FABQwork, n = 7; FABQphysical, n = 2; Relaxation therapy group, FIQtotal, n = 1; SF36 PCS and MCS, n = 2; FABQwork, n = 9. Significant p values are shown in bold text. 6MWT six-minute walk test, FIQ fibromyalgia impact questionnaire, VAS visual analog scale, SF36 short-form 36, PDI pain disability index, CPAQ chronic pain acceptance questionnaire, FABQ fear avoidance beliefs questionnaire